#
Microskin
my account
cart
Investors

17th March 2014

Results of Annual General Meeting

Microskin PLC (GXG:MSKN) (the "company") wishes to inform the market that the Company held its annual general meeting of shareholders at  The Boardroom, 1 Berkeley Street, Mayfair, London W1J 8DJ United Kingdom at 10:00 hours (GMT) on the 14th March 2014.

The results of the meeting are as below

Removal from the GXG

Following members approval at the AGM for the Company's removal from the First Quote Exchange, the Company has today given notice to GXG that the Company wishes to be removed from GXG on 15th April 2014, being 21 business days from the date of notice as per Listing Rule 13.1

Resignation of Company Secretary

The Company wishes to inform the Market that David Mahon has resigned as Company Secretary effective today, 17th March 2014 the Company will appoint a replacement in due course.

For further information about this update contact

Barry Amor Tel: +61 7 3260 6125

MEDIA RELEASE

9th August 2013

 

Microskin announces patent to be granted in the US

 

Microskin PLC (GXG: MSKN), a revolutionary second skin technology company, announced today that it has received advice from the US Patent and Trademark Office that their patent will be granted.

The company produces a simulated second skin individually formulated to colour correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says the patent marks a major milestone in overseas expansion for Microskin PLC.

“This patent will protect our intellectual and material property within Microskin PLC, excluding others from making, using, offering for sale, selling or importing our product throughout the US,” Mr Amor says.

“Receiving a patent for Microskin in the US ensures our hard work and years of research are respected in the industry.

 

“We believe the US patent will assist in the granting of patents in China and Australia, with patents already approved in Canada, India and New Zealand.”

 

Statistics show the average time for patent applications to be processed in the US in 2012 was 2.7 years.

 

“We have been at the forefront of research and development of a second skin-technology, so to be granted this patent after such rigorous processing is a great achievement for Microskin,” Mr Amor says.

 

The US is already home to two Microskin clinics in New York and California.

 

 

 

 

 

MEDIA RELEASE

25 July 2013

 

Microskin granted approval from Saudi FDA

 

Microskin PLC (GXG: MSKN), a revolutionary second skin technology company, has received approval from the Saudi FDA to import its product allowing operations to commence immediately in Riyadh, Saudi Arabia.

 

The company produces a simulated second skin individually formulated to color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says approval from the Saudi FDA marks a major milestone for Microskin’s development in the Middle East, as FDA process’ can take up to five years to complete.

“The Middle East has a high incidence of vitiligo and other skin conditions, so receiving approval from the Saudi FDA provides us with a great opportunity to reach new clients and provide them with effective solutions for their skin issues,” Mr Amor says.

“Our agreement with The Light Clinic in Riyadh, which is considered to be one of the largest vitiligo treatment centres in the world, will see that Microskin is available to approximately 18,000 patients and eight sister clinics.

“We intend to use this momentum to investigate other franchising options in Jedda followed by Dubai.”

The overseas expansion of Microskin in the Middle East has furthered the company’s geographic reach, capturing new markets that weren’t previously exposed to the product. 

Approval granted by the Saudi FDA to import Microskin into Saudi Arabia is an indicator of the company’s ability to garner attention worldwide.

Microskin have utilised a franchise model to expand the business since 2010, when they opened their first clinic outside Australia at the Laser and Skin Surgery Center of New York.

Each clinic has facilities to undertake computer skin tone matching for patients, as well as training in how to apply the product to their own skin.

For more information visit www.microskin.com.au

19 March 2013

Media Release

Microskin PLC admitted to trade on GXG exchange

BRISBANE, Australia – Microskin PLC, a second skin technology company, announced today that it had been admitted to trading on the GXG Markets OTC immediately under the symbol  MSKN.

The company produces a revolutionary simulated second skin individually formulated to color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says admittance to the GXG was a major milestone in the company’s eight-year history.

“We have been at the forefront of the research and development of a second-skin technology which helps people suffering from all sorts of skin conditions,” Mr Amor says.

“It has required a lot of hard work and effort to bring us to where we are now which includes a sizeable international franchise network.

“Being able to trade on an international market will not only give us a more competitive environment for raising capital and trading of shares, but also takes us into a new phase of expansion.”

Microskin appointed first quotation introduction partners Stepping Stone Equity to complete the process.

For more information visit www.microskin.com.au

 

 

Australian second skin technology company to list on UK exchange

Media Release:

27 February 2013

Australian second skin technology company to list on UK exchange
Australian skin simulation technology company Microskin has announced its intention to list
on the UK based GXG exchange.

The company produces a revolutionary simulated second skin individually formulated to
color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin has already achieved considerable success both in Australia and overseas
including establishing franchises in the US, Europe, the Middle East and Indonesia.

The Executive Chairman, Barry Amor, says Microskin is now in a position to be able to list on
an exchange, and the GXG offered the best initial option for international expansion.

“Microskin’s listing will provide the necessary capital to support our international expansion
plans, particularly to establish further franchises,” Mr Amor says.

“The GXG is a European regulated market and provides a more competitive environment for
raising capital and trading of shares, especially on a global scale.

“It will also give us access to a much larger consumer base, so all these factors make it an
attractive option to list.”

Microskin has appointed corporate advisors Stepping Stone Equity to complete the process
and to finalise a prospectus to comply with the exchange’s official list, paving the way for a
dual listing on the Frankfurt Stock Exchange.

Mr Amor says Microskin’s successful and profitable track record over the past eight years
has enabled it to build a sizeable franchise network, however liquidity in the company is
required for further expansion.

“While we have achieved considerable domestic and international success to date, we are
now focussing our energies on new markets which will give us a far greater opportunity to
further our expansion plans,” Mr Amor says.

“We are already well underway with negotiations for a number of new franchise agreements
and product development to supplement our flagship offering.

“Our listing strategy will provide us with both the capital and opportunities to continue our
research and development and help to secure our place as a dominant player in our industry
worldwide.”

The listing proposal has already been presented to Microskin shareholders for final approval
and is expected to be completed in the coming days.
For more information or to register interest in Microskin’s listing visit
www.microskin.com.au

ENDS

For all media enquiries contact Bruce Nelson on +61 (0) 423 403 449.

About Microskin

The concept of Microskin, a world-first skin simulation technology, was originally conceived
after realising that make-up was the only method of concealing or camouflaging skin
conditions. What transpired after many years of research into cosmetic chemistry as well as
developing specially designed software used to read human skin, was a system to develop a
spray-on simulated application individually formulated for each client’s skin. Microskin will
not rub off, is completely waterproof, allows the skin to breath and sweat, and lasts for
several days. Since the opening of its first clinic in Brisbane in July 2005, Microskin has
assisted people from all over the world with skin related conditions such as, vitiligo,
birthmarks, burns, eczema, lupus, keloid scarring.

Search
 
About us

The concept of Microskin, a world-first skin simulation technology, was originally conceived after we realised that make-up was the only method of concealing or camouflaging skin conditions (more)

Microskin Terms & Conditions

Skin Conditions